Discover New Binders
Bring a target and intended application. Target readiness, library chemistry and counter-selection are reviewed before selection, sequence analysis and representative hit nomination.
From library diversity to confirmed hits
Discover target-binding macrocycles and confirm which hits merit further development.
CD ComputaBio connects library selection with independent peptide synthesis, binding confirmation and application-focused testing. Start with a target, an enriched hit list or a panel of designed candidates.
Three ways to begin
Cyclic peptide screening searches a chemically defined library for molecules associated with a target or assay response. Hit validation then asks whether individually prepared peptides reproduce that behavior and provide useful binding, selectivity or functional evidence.
Our peptide drug discovery support connects these stages around the next experimental decision. Screening campaigns and stand-alone validation projects can be scoped separately, so the work begins where your program needs evidence.
Bring a target and intended application. Target readiness, library chemistry and counter-selection are reviewed before selection, sequence analysis and representative hit nomination.
Provide a hit list from an internal or external screen. We review the original molecular format, independently prepare selected peptides and assess reproducibility in suitable assays.
Move computational candidates into individual synthesis and testing. Candidates from AI-guided de novo cyclic peptide design can enter validation directly.
Your next step: share the target, existing sequences or design package. We will identify the appropriate entry stage and outline the material and assay requirements.
Define the biological question
A productive screen begins with an accessible, relevant target. We review construct boundaries, species, tags, purity, activity and available material, together with structural information and known ligands. For receptors and complexes, conformation, glycosylation and membrane context help determine whether a purified construct presents the desired surface.
Target immobilization and capture chemistry enter the experimental plan. Controls against affinity tags, beads and support surfaces help distinguish target recognition from background retention. Close homologs or designated counter-targets address a separate question: biological selectivity.
Cross-species binding, competitive inhibition and targeting applications require different selection pressures and confirmation assays. These objectives define the proposed controls, assay conditions and criteria for moving between stages.
Send target specifications for a screening plan →Chemistry shapes discovery
Ring size, residue choices and closure chemistry determine which molecular features a screen can explore. Library selection balances target fit, translation compatibility and independent synthesis.
| Project route | Best starting point | Design and confirmation focus |
|---|---|---|
| mRNA display selection | A target requiring exploration of a broad encoded sequence space. | Review randomized positions, encoded residues, cyclization chemistry, target presentation and selection controls. |
| Focused synthetic libraries | A known motif, scaffold or initial structure–activity hypothesis. | Prepare defined analogs and compare binding or functional responses using consistent material specifications. |
| Client-supplied candidate panels | Existing screening hits or computationally designed macrocycles. | Reconcile complete chemical definitions, sample quality and the original evidence before testing individual compounds. |
Existing formats provide a practical starting point when their ring architecture fits the target. Custom projects can vary random-region length, residue composition or cyclization design. The brief distinguishes total peptide length from the variable region and theoretical sequence space from experimentally constructed diversity.
Custom building blocks are assessed for translation, incorporation and reaction compatibility. Chemistry available during subsequent solid-phase synthesis may extend beyond the encoded library. Our peptide library design services help connect discovery objectives with a practical candidate space.
A staged discovery workflow
mRNA display links peptides to their encoding nucleic acids, allowing retained sequences to be recovered and amplified. Selection conditions and analytical checkpoints are adjusted around the target, background behavior and diversity of the emerging families.
Review target handling, capture conditions, library format and control materials. Establish the readouts that will indicate useful recovery and acceptable background.
Decision: readiness for the first selection.
Apply the agreed selection and background-depletion conditions. Tune target concentration, washing or competition as evidence emerges rather than using stringency as a fixed recipe.
Decision: how to refine the next round.
Analyze available round-by-round sequence data, relative abundance, family patterns and control recovery. Flag families enriched against capture reagents or designated counter-targets.
Decision: which families have useful support.
Select chemically feasible sequences across distinct families. Balance enrichment evidence with diversity so independent testing examines several binding hypotheses.
Decision: the synthesis and confirmation panel.
Sequence abundance and enrichment guide nomination; affinity is measured on individual peptides. Round count is agreed in the campaign plan and reviewed against enrichment, background and sequence convergence.
The critical transition

Each hit is defined by sequence, residue stereochemistry, noncanonical building blocks, termini and cyclization connectivity. We compare the displayed construct with the intended free peptide, including linker remnants or terminal changes that may influence binding.
Selected hits and controls are synthesized and purified to the agreed specifications. HPLC and LC-MS establish chromatographic purity and mass consistency; complex connectivity, isomer or stereochemistry questions may require complementary characterization.
Linear, inactive, scrambled or site-mutated controls are chosen for the specific hypothesis. Sample handling records cover stock preparation, solvent, solubility and storage so biological comparisons can be interpreted against the material actually tested.
Evidence at the level your program needs
Validation is organized around distinct questions. Direct binding establishes target recognition; competition and function test how that recognition relates to the intended biological effect. Each assay module has defined controls, concentration ranges and repeat measurements.
| Validation layer | Experimental question | Typical evidence |
|---|---|---|
| Binding confirmation | Does the independent peptide bind the target? | Concentration-dependent measurements using suitable SPR, BLI or an alternative format; affinity analysis where supported. |
| Specificity assessment | Does recognition persist after background and homolog comparisons? | Tag and matrix controls, related-protein counterscreens and species comparisons within the agreed panel. |
| Competition studies | Does the peptide affect the intended ligand interaction? | Displacement or competition measurements supporting overlap or interference with a known interaction. |
| Functional confirmation | Does binding produce the desired response? | Biochemical inhibition, receptor signaling or a relevant cellular endpoint, with IC50 or EC50 where appropriate. |
| Application-focused testing | Does the hit work in the proposed downstream format? | Cell-surface recognition, internalization or retained binding after labeling or conjugation. |
Small-peptide signals, immobilization orientation, nonspecific retention and mass transport affect biophysical measurements. Reference surfaces, appropriate controls, replicate design and inspection of raw traces support meaningful interpretation. Kinetic parameters are reported when the experimental response and fit justify the model.
Confirmation can change the detection principle, labeling scheme or target presentation to investigate an apparent hit. SPR and BLI may share immobilization effects; an additional format should address the suspected source of bias. KD, IC50 and EC50 are reported with their assay conditions because they describe different measurements.
Share chemical structures, purity records, stock conditions and the original assay results. We can scope a confirmation panel around the evidence you already hold.
Published discovery-to-validation example
A published ADO study combined mRNA display with peptide synthesis, SPR and enzyme assays. The selected sequences showed different binding and inhibitory behavior after individual characterization, illustrating why enrichment, affinity and function are separate stages of evidence.1
The figure brings these stages together: library selection, nominated sequences, initial inhibition and detailed characterization of selected peptides. It provides a literature example for planning follow-up experiments; project-specific choices depend on the target and intended use.

Turn results into next steps
Hit prioritization combines reproducibility, chemical quality, affinity, selectivity, function, solubility and family diversity. Acceptance criteria reflect the application: a research probe, receptor modulator and targeting ligand may require different evidence.
Independent binding and relevant biological results support focused analog design. Define the substitutions, ring changes or property studies that can improve the most informative families.
Format-dependent responses or disagreement between binding and function trigger targeted checks. Examine compound handling, controls, construct relevance and assay interference before expanding the series.
When free peptides do not reproduce the expected signal, review library chemistry, target presentation and selection conditions. The report proposes a revised experiment or alternative starting point.
For confirmed families, cyclic peptide structure modeling can support substitution hypotheses, while peptide developability assessment helps prioritize property questions. Programs seeking oral exposure can continue into our oral cyclic peptide discovery services.
A traceable package for project review
Deliverables follow the agreed entry stage and experimental scope. Sample identifiers connect chemical definitions, analytical records, assay outputs and the final candidate ranking.
Target format, library choice, controls, counter-selection plan and stage criteria for the discovery campaign.
Agreed round data, sequence processing, enrichment trends, family assignments and nomination rationale.
Sequences, stereochemistry, modifications, cyclization definitions, batch identifiers and analytical records.
Assay conditions, raw traces or response data, controls, repeats and supported affinity or kinetic analyses.
Contracted competition, biochemical, cell-based or conjugation-related results with their experimental context.
An integrated ranking, remaining evidence gaps and recommendations for confirmation or focused optimization.
The proposal specifies candidate numbers, selection rounds, synthesis quantity and purity, assay panels and data files, including NGS files where applicable.
Select the assay for the application
Combine purified-target binding with cell-surface or competition studies when the native environment affects accessibility. Define whether the goal is simple recognition or receptor modulation.
Follow direct binding with interaction disruption or enzyme assays. For intracellular programs, cellular activity and target-engagement studies address exposure and biological relevance.
Prioritize ligands with a practical conjugation position. Compare the parent peptide with the intended labeled or conjugated format, then assess uptake or retention as required.
Confirm recognition before introducing fluorophores or affinity handles. Matched inactive controls and labeled-versus-unlabeled comparisons help support mechanistic interpretation.
Project questions
Yes. Share the construct, tags, buffer, quantity and available activity data. These details support a target-readiness review and selection strategy.
Yes. Provide complete molecular definitions, the original display or assay format and supporting results. Validation can begin with resynthesis or qualified existing samples.
Yes. Chemically defined candidates can proceed to individual synthesis, quality assessment and binding or functional testing. The testing plan follows the design hypothesis.
Custom residues and ring chemistries are reviewed for incorporation, cyclization and synthesis compatibility. Share chemical structures so feasibility and any preliminary work can be assessed.
The proposal sets an initial campaign scope and review points. Criteria incorporate enrichment, background, chemical quality and independent assays in relation to the intended application.
We review peptide identity, handling, target state and screening-format effects, then recommend focused confirmation or a revised selection strategy based on the observed evidence.
Make your next discovery decision
Share your target, available materials, screening history and intended application. We will help define the library strategy, confirmation assays and evidence needed to move your program forward.
For sequences, structures or supporting records, email contact@computabio.com.
Submit your project details below, and our team will respond within 24 hours.
Talk to our technical team about your project!
I Want To Talk